Skip to main content
. Author manuscript; available in PMC: 2022 Aug 9.
Published in final edited form as: Acc Chem Res. 2020 Aug 18;53(9):1739–1748. doi: 10.1021/acs.accounts.0c00313

Figure 2.

Figure 2.

(a) Principle of conventional cancer vaccine by systemically injecting tumor antigens vs in situ cancer vaccine by intratumorally injecting immunoadjuvants to stimulate tumor antigen release. (b) Schematic showing nMOF-mediated local treatment, including PDT, RT, RT-RDT, and CDT, to kill tumor cells via ROS generation and augment innate immunity for synergistic effects with CBI.